RETIRESAFE

Worked within the Protect Medicare Part D working group to protect and improve Medicare Part D. Continued our support of 340B reform including our support of HR 4710, the Pause Act, which would improve oversight and increase program accountability. In January RetireSafe commented on the Proposed Rule on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses released in the Federal Register on November 30, 2018. We proposed that the only meaningful change would be one that lowered the patients out-ot-pocket costs. Sent a letter to the Administration concerning some of the proposed changes to Medicare, especially Part D, that we felt threatened the access and safety of older Americans. talked about importance of vaccinations and accessibility. discussed our stance against drug importation.

Client expense: $106,000 · Firm income: —

Matched citations: HR 4710

Worked within the Protect Medicare Part D working group to protect and improve Medicare Part D. Continued our support of 340B reform including our support of HR 4710, the Pause Act, which would improve oversight and increase program accountability. In January RetireSafe commented on the Proposed Rule on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses released in the Federal Register on November 30, 2018. We proposed that the only meaningful change would be one that lowered the patients out-ot-pocket costs. Sent a letter to the Administration concerning some of the proposed changes to Medicare, especially Part D, that we felt threatened the access and safety of older Americans. talked about importance of vaccinations and accessibility. discussed our stance against drug importation.

Client expense: $390,000 · Firm income: —

Matched citations: HR 4710

Worked within the Protect Medicare Part D working group to protect and improve Medicare Part D. Continued our support of 340B reform including our support of HR 4710, the Pause Act, which would improve oversight and increase program accountability. In January RetireSafe commented on the Proposed Rule on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses released in the Federal Register on November 30, 2018. We proposed that the only meaningful change would be one that lowered the patients out-ot-pocket costs. Sent a letter to the Administration concerning some of the proposed changes to Medicare, especially Part D, that we felt threatened the access and safety of older Americans. talked about importance of vaccinations and accessibility. discussed our stance against drug importation.

Client expense: $125,000 · Firm income: —

Matched citations: HR 4710

Worked within the Protect Medicare Part D working group to protect and improve Medicare Part D. Continued our support of 340B reform including our support of HR 4710, the Pause Act, which would improve oversight and increase program accountability. In January RetireSafe commented on the Proposed Rule on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses released in the Federal Register on November 30, 2018. We proposed that the only meaningful change would be one that lowered the patients out-ot-pocket costs. Sent a letter to the Administration concerning some of the proposed changes to Medicare, especially Part D, that we felt threatened the access and safety of older Americans. talked about importance of vaccinations and accessibility. discussed our stance against drug importation.

Client expense: $38,750 · Firm income: —

Matched citations: HR 4710

Worked within the Protect Medicare Part D working group to protect and improve Medicare Part D. Continued our support of 340B reform including our support of HR 4710, the Pause Act, which would improve oversight and increase program accountability. In January RetireSafe commented on the Proposed Rule on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses released in the Federal Register on November 30, 2018. We proposed that the only meaningful change would be one that lowered the patients out-ot-pocket costs. Sent a letter to the Administration concerning some of the proposed changes to Medicare, especially Part D, that we felt threatened the access and safety of older Americans. talked about importance of vaccinations and accessibility. discussed our stance against drug importation.

Client expense: $255,600 · Firm income: —

Matched citations: HR 4710

Worked within the Protect Medicare Part D working group to protect and improve Medicare Part D. Continued our support of 340B reform including our support of HR 4710, the Pause Act, which would improve oversight and increase program accountability. In January RetireSafe commented on the Proposed Rule on Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses released in the Federal Register on November 30, 2018. We proposed that the only meaningful change would be one that lowered the patients out-ot-pocket costs. Sent a letter to the Administration concerning some of the proposed changes to Medicare, especially Part D, that we felt threatened the access and safety of older Americans. talked about importance of vaccinations and accessibility. discussed our stance against drug importation.

Client expense: $68,787 · Firm income: —

Matched citations: HR 4710

Support the quick implementation of the 21st Century Cures Act, specifically the provisions in the Act designed to speed up the Advisory Committee on Immunization Practices (ACIP) process through an established timeline so that much-needed new vaccines can be approved for coverage and use. Joined with numerous patient advocate organizations to urge Congress to maintain a strong and secure patent system that recognizes the rights of legitimate patent owners and addresses the new forms of abuses that have emerged in both the courts and at the U.S. Patent & Trademark Office (PTO), especially in consideration of the critical nature of strong patent protection in the development of new therapies and treatments that could benefit millions of patients suffering with substantial unmet medical needs. With National Health Council, urged CMS to include accurate drug-specific out-of-pocket (OOP) costs in the proposed OOP cost estimator under development for the federally-facilitated marketplaces. RetireSafe encouraged Members of Congress to hold a formal hearing to review FDA policy and guidance regarding the safe usage of biosimilar drugs. And, with other patient groups, advocated Risk Evaluation and Mitigation Strategies (REMS) and other rigorous safeguards to ensure the safe use of biosimilar drugs, especially for any federally mandated use. We also support the proposal that patient cost-sharing for most tiers and metal levels utilize reasonable cost-sharing, and oppose the use of coinsurance for the Specialty Drug Tier. We also repeated previous recommendations, and some new ones that would better protect enrollees access to needed prescription drugs, in addition to recommendations that would better ensure critical continuity of care. RetireSafe continues to join with other patient groups to urge the Food and Drug Administration (FDA) to require distinct, unique naming for any and all biosimilar drugs approved for use in the United States. We support the FDAs leadership in creating a system of distinguishable names for all biologic medicines, including biosimilars and interchangeable products. This system recognizes the fact that biosimilars are not exact copies of their reference products, enhances patient safety and promotes pharmacovigilance. RetireSafe supports HR 1920 which will correct the reduced payments to community oncologists. Signed onto a letter to President Trump with other organizations highlighting and promoting the value of vaccines. As a member of the Partnership for Safe Medicines, we supported a letter to Senators reminding them of the safety aspects involved with drug importation. As part of Alliance for Safe Biologics we encouraged the release of final guidance that supported the safe introductions of biosimilars.

Client expense: $6,742 · Firm income: —

Matched citations: HR 1920

RetireSafe joined with the Healthcare Leadership Council and others to support the Protecting Seniors Access to Medicare Act, Worked with the MAPRx coalition and others to protect Medicare Part D by opposing the elimination of the non-interference and opposing recommendations to allow the importation of medicines. RetireSafe joined with the Alliance for Safe Biological Medicines to influence the regulations and rules at FDA to ensure that biosimilars are safe and trusted. Worked specifically to prevent the non-medical switching of biologics and/or biosimilars. RetireSafe lobbied against proposed legislation that would allow the importation of prescription drugs and against the repeal of the non-interference clause. Joined with AIR340b to advocate for reform of the 340b drug discount program. Submitted comments on the CMS proposed changes to Medicare Part B. Submitted a letter to CMS concerning the coverage gap "cliff" that is facing older Americans. Continued our support of S. 2769, the Opioid Addiction Plan Act. Released a statement on the need to preserve the 6 protected classes of Medicare Part D drugs.

Client expense: $6,742 · Firm income: —

Matched citations: S. 2769

RetireSafe joined with the Healthcare Leadership Council and others to support the Protecting Seniors Access to Medicare Act, (H.R. 849 and S. 360) to repeal the Independent Payment Advisory Board (IPAB), authorized under the Patient Protection and Affordable Care Act. Visited multiple House and Senate offices in Washington and in their state and districts is support of IPAB repeal. As part of the PACT coalition lobbied in support of HR 1920 and S 1304 to cancel the prompt pay discount for Part B medicines. Worked with the Protect Medicare Part D Working Group and others to protect Medicare Part D by opposing the elimination of the non-interference and opposing recommendations to allow the importation of medicines. RetireSafe joined with the Alliance for Safe Biological Medicines to influence the regulations and rules at FDA to ensure that biosimilars are safe and trusted. Worked specifically to prevent the non-medical switching of biologics and/or biosimilars. RetireSafe lobbied against proposed legislation that would allow the importation of prescription drugs and against the repeal of the non-interference clause. Joined with AIR340b to advocate for reform of the 340b drug discount program.

Client expense: $7,192 · Firm income: —

Matched citations: HR 1920

Support the quick implementation of the 21st Century Cures Act, specifically the provisions in the Act designed to speed up the Advisory Committee on Immunization Practices (ACIP) process through an established timeline so that much-needed new vaccines can be approved for coverage and use. Joined with numerous patient advocate organizations to urge Congress to maintain a strong and secure patent system that recognizes the rights of legitimate patent owners and addresses the new forms of abuses that have emerged in both the courts and at the U.S. Patent & Trademark Office (PTO), especially in consideration of the critical nature of strong patent protection in the development of new therapies and treatments that could benefit millions of patients suffering with substantial unmet medical needs. RetireSafe supported maintaining 12 years of data exclusivity for biologic drugs under the Trans-Pacific Partnership (TTP) trade agreement as a key U.S. priority. With National Health Council, urged CMS to include accurate drug-specific out-of-pocket (OOP) costs in the proposed OOP cost estimator under development for the federally-facilitated marketplaces. RetireSafe encouraged Members of Congress to hold a formal hearing to review FDA policy and guidance regarding the safe usage of biosimilar drugs. And, with other patient groups, advocated Risk Evaluation and Mitigation Strategies (REMS) and other rigorous safeguards to ensure the safe use of biosimilar drugs, especially for any federally mandated use. Those comments included support for the proposed Standard Benefit Option (SBO) that will better enable consumers to compare plans and make informed choices. While we generally supported the SBO design, we expressed concern over the use of the Specialty Drug Tier and its use as a broad catch-all class insurers use to increase patient costs. We urged HHS to make all medications not subject to a deductible in all metal levels and tier levels, as we strongly believe that prescription medications should not be subject to a plans deductible. We also support the proposal that patient cost-sharing for most tiers and metal levels utilize reasonable cost-sharing, and oppose the use of coinsurance for the Specialty Drug Tier. We also repeated previous recommendations, and some new ones that would better protect enrollees access to needed prescription drugs, in addition to recommendations that would better ensure critical continuity of care. In addition, RetireSafe joined with 197 patient and community organizations to comment on the Office for Civil Rights, ACA Non-discrimination Proposed Rule (RIN 0945-AA02). We were especially interested in one key ACA provision, Section 1557, which prohibits discrimination in the health care system on the basis of race, color, national origin, sex, age or disability RetireSafe continues to join with other patient groups to urge the Food and Drug Administration (FDA) to require distinct, unique naming for any and all biosimilar drugs approved for use in the United States. We support the FDAs leadership in creating a system of distinguishable names for all biologic medicines, including biosimilars and interchangeable products. This system recognizes the fact that biosimilars are not exact copies of their reference products, enhances patient safety and promotes pharmacovigilance. RetireSafe supports HR 1920 which will correct the reduced payments to community oncologists. RetireSafe joined with the Osteoporosis Foundation in a letter to Congress asking them to preserve Medicare part D by not eliminating the non-interference clause. Singed onto a letter to President Trump with other organizations highlighting and promoting the value of vaccines. As member of the Patients for Biologics Safety & Access (PBSA) coalition we supported two letters sent to CMS in regard to biologic interchangeable products. As a member of the Partnership for Safe Medicines, we supported a letter to Senators reminding them of the safety aspects involved with drug importation. As part of Alliance for Safe Biologics we encouraged the release of final guidance that supported the safe introductions of biosimilars.

Client expense: $7,192 · Firm income: —

Matched citations: HR 1920

RetireSafe spoke out on the need to reduce the corporate tax in America and in favor of HR 2016 CPI for Seniors Act.

Client expense: $7,192 · Firm income: —

Matched citations: HR 2016

RetireSafe joined with the Healthcare Leadership Council and others to support the Protecting Seniors Access to Medicare Act, (H.R. 849 and S. 360) to repeal the Independent Payment Advisory Board (IPAB), authorized under the Patient Protection and Affordable Care Act. Visited multiple House and Senate offices in Washington and in their state and districts is support of IPAB repeal. As part of the PACT coalition lobbied in support of HR 1920 and S 1304 to cancel the prompt pay discount for Part B medicines. Worked with the Protect Medicare Part D Working Group and others to protect Medicare Part D by opposing the elimination of the non-interference and opposing recommendations to allow the importation of medicines. RetireSafe joined with the Alliance for Safe Biological Medicines to influence the regulations and rules at FDA to ensure that biosimilars are safe and trusted. Worked specifically to prevent the non-medical switching of biologics and/or biosimilars. RetireSafe lobbied against proposed legislation that would allow the importation of prescription drugs and against the repeal of the non-interference clause. Joined with AIR340b to advocate for reform of the 340b drug discount program.

Client expense: $7,192 · Firm income: —

Matched citations: H.R. 849

RetireSafe joined with the Healthcare Leadership Council and others to support the Protecting Seniors Access to Medicare Act, (H.R. 849 and S. 360) to repeal the Independent Payment Advisory Board (IPAB), authorized under the Patient Protection and Affordable Care Act. Visited multiple House and Senate offices in Washington and in their state and districts is support of IPAB repeal. As part of the PACT coalition lobbied in support of HR 1920 and S 1304 to cancel the prompt pay discount for Part B medicines. Worked with the Protect Medicare Part D Working Group and others to protect Medicare Part D by opposing the elimination of the non-interference and opposing recommendations to allow the importation of medicines. RetireSafe joined with the Alliance for Safe Biological Medicines to influence the regulations and rules at FDA to ensure that biosimilars are safe and trusted. Worked specifically to prevent the non-medical switching of biologics and/or biosimilars. RetireSafe lobbied against proposed legislation that would allow the importation of prescription drugs and against the repeal of the non-interference clause. Joined with AIR340b to advocate for reform of the 340b drug discount program.

Client expense: $7,192 · Firm income: —

Matched citations: S 1304

RetireSafe joined with the Healthcare Leadership Council and others to support the Protecting Seniors Access to Medicare Act, (H.R. 849 and S. 360) to repeal the Independent Payment Advisory Board (IPAB), authorized under the Patient Protection and Affordable Care Act. Visited multiple House and Senate offices in Washington and in their state and districts is support of IPAB repeal. As part of the PACT coalition lobbied in support of HR 1920 and S 1304 to cancel the prompt pay discount for Part B medicines. Worked with the Protect Medicare Part D Working Group and others to protect Medicare Part D by opposing the elimination of the non-interference and opposing recommendations to allow the importation of medicines. RetireSafe joined with the Alliance for Safe Biological Medicines to influence the regulations and rules at FDA to ensure that biosimilars are safe and trusted. Worked specifically to prevent the non-medical switching of biologics and/or biosimilars. RetireSafe lobbied against proposed legislation that would allow the importation of prescription drugs and against the repeal of the non-interference clause. Joined with AIR340b to advocate for reform of the 340b drug discount program.

Client expense: $7,192 · Firm income: —

Matched citations: S. 360

RetireSafe joined with the Healthcare Leadership Council and others to support the Protecting Seniors Access to Medicare Act, (H.R. 849 and S. 360) to repeal the Independent Payment Advisory Board (IPAB), authorized under the Patient Protection and Affordable Care Act. Visited multiple House and Senate offices in Washington and in their state and districts is support of IPAB repeal. As part of the PACT coalition lobbied in support of HR 1920 and S 1304 to cancel the prompt pay discount for Part B medicines. Worked with the Protect Medicare Part D Working Group and others to protect Medicare Part D by opposing the elimination of the non-interference and opposing recommendations to allow the importation of medicines. RetireSafe joined with the Alliance for Safe Biological Medicines to influence the regulations and rules at FDA to ensure that biosimilars are safe and trusted. Worked specifically to prevent the non-medical switching of biologics and/or biosimilars. RetireSafe lobbied against proposed legislation that would allow the importation of prescription drugs and against the repeal of the non-interference clause. Joined with AIR340b to advocate for reform of the 340b drug discount program.

Client expense: $11,129 · Firm income: —

Matched citations: HR 1920

Support the quick implementation of the 21st Century Cures Act, specifically the provisions in the Act designed to speed up the Advisory Committee on Immunization Practices (ACIP) process through an established timeline so that much-needed new vaccines can be approved for coverage and use. Joined with numerous patient advocate organizations to urge Congress to maintain a strong and secure patent system that recognizes the rights of legitimate patent owners and addresses the new forms of abuses that have emerged in both the courts and at the U.S. Patent & Trademark Office (PTO), especially in consideration of the critical nature of strong patent protection in the development of new therapies and treatments that could benefit millions of patients suffering with substantial unmet medical needs. RetireSafe supported maintaining 12 years of data exclusivity for biologic drugs under the Trans-Pacific Partnership (TTP) trade agreement as a key U.S. priority. With National Health Council, urged CMS to include accurate drug-specific out-of-pocket (OOP) costs in the proposed OOP cost estimator under development for the federally-facilitated marketplaces. RetireSafe encouraged Members of Congress to hold a formal hearing to review FDA policy and guidance regarding the safe usage of biosimilar drugs. And, with other patient groups, advocated Risk Evaluation and Mitigation Strategies (REMS) and other rigorous safeguards to ensure the safe use of biosimilar drugs, especially for any federally mandated use. Those comments included support for the proposed Standard Benefit Option (SBO) that will better enable consumers to compare plans and make informed choices. While we generally supported the SBO design, we expressed concern over the use of the Specialty Drug Tier and its use as a broad catch-all class insurers use to increase patient costs. We urged HHS to make all medications not subject to a deductible in all metal levels and tier levels, as we strongly believe that prescription medications should not be subject to a plans deductible. We also support the proposal that patient cost-sharing for most tiers and metal levels utilize reasonable cost-sharing, and oppose the use of coinsurance for the Specialty Drug Tier. We also repeated previous recommendations, and some new ones that would better protect enrollees access to needed prescription drugs, in addition to recommendations that would better ensure critical continuity of care. In addition, RetireSafe joined with 197 patient and community organizations to comment on the Office for Civil Rights, ACA Non-discrimination Proposed Rule (RIN 0945-AA02). We were especially interested in one key ACA provision, Section 1557, which prohibits discrimination in the health care system on the basis of race, color, national origin, sex, age or disability RetireSafe continues to join with other patient groups to urge the Food and Drug Administration (FDA) to require distinct, unique naming for any and all biosimilar drugs approved for use in the United States. We support the FDAs leadership in creating a system of distinguishable names for all biologic medicines, including biosimilars and interchangeable products. This system recognizes the fact that biosimilars are not exact copies of their reference products, enhances patient safety and promotes pharmacovigilance. RetireSafe supports HR 1920 which will correct the reduced payments to community oncologists. RetireSafe joined with the Osteoporosis Foundation in a letter to Congress asking them to preserve Medicare part D by not eliminating the non-interference clause. Singed onto a letter to President Trump with other organizations highlighting and promoting the value of vaccines. As member of the Patients for Biologics Safety & Access (PBSA) coalition we supported two letters sent to CMS in regard to biologic interchangeable products. As a member of the Partnership for Safe Medicines, we supported a letter to Senators reminding them of the safety aspects involved with drug importation. As part of Alliance for Safe Biologics we encouraged the release of final guidance that supported the safe introductions of biosimilars.

Client expense: $11,129 · Firm income: —

Matched citations: HR 1920

RetireSafe spoke out on the need to reduce the corporate tax in America and in favor of HR 2016 CPI for Seniors Act.

Client expense: $11,129 · Firm income: —

Matched citations: HR 2016

RetireSafe joined with the Healthcare Leadership Council and others to support the Protecting Seniors Access to Medicare Act, (H.R. 849 and S. 360) to repeal the Independent Payment Advisory Board (IPAB), authorized under the Patient Protection and Affordable Care Act. Visited multiple House and Senate offices in Washington and in their state and districts is support of IPAB repeal. As part of the PACT coalition lobbied in support of HR 1920 and S 1304 to cancel the prompt pay discount for Part B medicines. Worked with the Protect Medicare Part D Working Group and others to protect Medicare Part D by opposing the elimination of the non-interference and opposing recommendations to allow the importation of medicines. RetireSafe joined with the Alliance for Safe Biological Medicines to influence the regulations and rules at FDA to ensure that biosimilars are safe and trusted. Worked specifically to prevent the non-medical switching of biologics and/or biosimilars. RetireSafe lobbied against proposed legislation that would allow the importation of prescription drugs and against the repeal of the non-interference clause. Joined with AIR340b to advocate for reform of the 340b drug discount program.

Client expense: $11,129 · Firm income: —

Matched citations: H.R. 849

RetireSafe joined with the Healthcare Leadership Council and others to support the Protecting Seniors Access to Medicare Act, (H.R. 849 and S. 360) to repeal the Independent Payment Advisory Board (IPAB), authorized under the Patient Protection and Affordable Care Act. Visited multiple House and Senate offices in Washington and in their state and districts is support of IPAB repeal. As part of the PACT coalition lobbied in support of HR 1920 and S 1304 to cancel the prompt pay discount for Part B medicines. Worked with the Protect Medicare Part D Working Group and others to protect Medicare Part D by opposing the elimination of the non-interference and opposing recommendations to allow the importation of medicines. RetireSafe joined with the Alliance for Safe Biological Medicines to influence the regulations and rules at FDA to ensure that biosimilars are safe and trusted. Worked specifically to prevent the non-medical switching of biologics and/or biosimilars. RetireSafe lobbied against proposed legislation that would allow the importation of prescription drugs and against the repeal of the non-interference clause. Joined with AIR340b to advocate for reform of the 340b drug discount program.

Client expense: $11,129 · Firm income: —

Matched citations: S 1304

RetireSafe joined with the Healthcare Leadership Council and others to support the Protecting Seniors Access to Medicare Act, (H.R. 849 and S. 360) to repeal the Independent Payment Advisory Board (IPAB), authorized under the Patient Protection and Affordable Care Act. Visited multiple House and Senate offices in Washington and in their state and districts is support of IPAB repeal. As part of the PACT coalition lobbied in support of HR 1920 and S 1304 to cancel the prompt pay discount for Part B medicines. Worked with the Protect Medicare Part D Working Group and others to protect Medicare Part D by opposing the elimination of the non-interference and opposing recommendations to allow the importation of medicines. RetireSafe joined with the Alliance for Safe Biological Medicines to influence the regulations and rules at FDA to ensure that biosimilars are safe and trusted. Worked specifically to prevent the non-medical switching of biologics and/or biosimilars. RetireSafe lobbied against proposed legislation that would allow the importation of prescription drugs and against the repeal of the non-interference clause. Joined with AIR340b to advocate for reform of the 340b drug discount program.

Client expense: $11,129 · Firm income: —

Matched citations: S. 360

Support the quick implementation of the 21st Century Cures Act, specifically the provisions in the Act designed to speed up the Advisory Committee on Immunization Practices (ACIP) process through an established timeline so that much-needed new vaccines can be approved for coverage and use. Joined with numerous patient advocate organizations to urge Congress to maintain a strong and secure patent system that recognizes the rights of legitimate patent owners and addresses the new forms of abuses that have emerged in both the courts and at the U.S. Patent & Trademark Office (PTO), especially in consideration of the critical nature of strong patent protection in the development of new therapies and treatments that could benefit millions of patients suffering with substantial unmet medical needs. RetireSafe supported maintaining 12 years of data exclusivity for biologic drugs under the Trans-Pacific Partnership (TTP) trade agreement as a key U.S. priority. With National Health Council, urged CMS to include accurate drug-specific out-of-pocket (OOP) costs in the proposed OOP cost estimator under development for the federally-facilitated marketplaces. RetireSafe encouraged Members of Congress to hold a formal hearing to review FDA policy and guidance regarding the safe usage of biosimilar drugs. And, with other patient groups, advocated Risk Evaluation and Mitigation Strategies (REMS) and other rigorous safeguards to ensure the safe use of biosimilar drugs, especially for any federally mandated use. Those comments included support for the proposed Standard Benefit Option (SBO) that will better enable consumers to compare plans and make informed choices. While we generally supported the SBO design, we expressed concern over the use of the Specialty Drug Tier and its use as a broad catch-all class insurers use to increase patient costs. We urged HHS to make all medications not subject to a deductible in all metal levels and tier levels, as we strongly believe that prescription medications should not be subject to a plans deductible. We also support the proposal that patient cost-sharing for most tiers and metal levels utilize reasonable cost-sharing, and oppose the use of coinsurance for the Specialty Drug Tier. We also repeated previous recommendations, and some new ones that would better protect enrollees access to needed prescription drugs, in addition to recommendations that would better ensure critical continuity of care. In addition, RetireSafe joined with 197 patient and community organizations to comment on the Office for Civil Rights, ACA Non-discrimination Proposed Rule (RIN 0945-AA02). We were especially interested in one key ACA provision, Section 1557, which prohibits discrimination in the health care system on the basis of race, color, national origin, sex, age or disability RetireSafe continues to join with other patient groups to urge the Food and Drug Administration (FDA) to require distinct, unique naming for any and all biosimilar drugs approved for use in the United States. We support the FDAs leadership in creating a system of distinguishable names for all biologic medicines, including biosimilars and interchangeable products. This system recognizes the fact that biosimilars are not exact copies of their reference products, enhances patient safety and promotes pharmacovigilance. RetireSafe supports HR 1920 which will correct the reduced payments to community oncologists. RetireSafe joined with the Osteoporosis Foundation in a letter to Congress asking them to preserve Medicare part D by not eliminating the non-interference clause. Singed onto a letter to President Trump with other organizations highlighting and promoting the value of vaccines. As member of the Patients for Biologics Safety & Access (PBSA) coalition we supported two letters sent to CMS in regard to biologic interchangeable products. As a member of the Partnership for Safe Medicines, we supported a letter to Senators reminding them of the safety aspects involved with drug importation. As part of Alliance for Safe Biologics we encouraged the release of final guidance that supported the safe introductions of biosimilars.

Client expense: $9,561 · Firm income: —

Matched citations: HR 1920